Valsartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 51655-655

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 51655-655). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 655 52 Master Bottle Label Approval Rev B 05 21)

Label for Valsartan and Hydrochlorothiazide Tablets USP 320 mg / 25 mg, oral film-coated tablets. The label indicates a package size of 30 tablets with NDC 51655-655-52, manufactured and repackaged by Northwind Health Company, LLC. It includes storage instructions and notes that the product is prescription only.*

FDA Label Image

Figure-1 (Valsartan Hctz Figure 1)

A line graph comparing the percentage of patients with systolic blood pressure (SBP) less than 140 mmHg against baseline SBP values (140 to 180 mmHg). The graph shows four groups: Valsartan HCT 320/25 mg (solid circles), Valsartan 320 mg (open triangles), Hydrochlorothiazide 25 mg (open squares), and Placebo (crosses).*

FDA Label Image

Figure-2 (Valsartan Hctz Figure 2)

A line graph showing the percentage of patients with diastolic blood pressure below 90 mmHg (% DBP<90) plotted against baseline DBP (mmHg) for four treatment groups: Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo. Each treatment's efficacy is represented by different symbols and lines across baseline DBP ranging from 90 to 110 mmHg.*

FDA Label Image

Figure-3 (Valsartan Hctz Figure 3)

A line graph showing the percentage of subjects achieving systolic blood pressure (SBP) below 130 mmHg across different baseline SBP values (140 to 180 mmHg). The graph compares four groups: Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo, with distinct markers for each group. The percentage of subjects achieving the target SBP is highest for Valsartan HCT 320/25 mg and lowest for placebo.*

FDA Label Image

Figure-4 (Valsartan Hctz Figure 4)

A line graph showing percentage of diastolic blood pressure (DBP) below 80 mmHg on the y-axis against baseline DBP (mmHg) on the x-axis. It compares four groups: Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, represented by different markers. The graph illustrates the efficacy of these treatments across baseline DBP values from 90 to 110 mmHg.*

FDA Label Image

Hctz-stru (Valsartan Hctz Hydrochlorothiazide)

Chemical structure diagram showing the molecular arrangement of the active ingredient in Valsartan and Hydrochlorothiazide tablets, film coated.*

FDA Label Image

Valsartan-str (Valsartan Hctz Valsartan)

Chemical structure diagram of the active ingredient Valsartan, showing its molecular configuration with labeled functional groups and bonds.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.